Open AccessP1214: SUBCUTANEOUS EPCORITAMAB + R‐CHOP FOR FIRST‐LINE TREATMENT OF PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE 1/2 UPDATE
Author(s) -
Clausen M. R.,
Offner F.,
Belada D.,
Brody J.,
Linton K. M.,
Karimi Y.,
Cordoba R.,
Snauwaert S.,
Abbas A.,
Wang L.,
Wu J.,
Elliott B.,
Falchi L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847720.26592.b6
Subject(s) - medicine , rituximab , vincristine , international prognostic index , prednisone , diffuse large b cell lymphoma , cyclophosphamide , chop , lymphoma , gastroenterology , oncology , refractory (planetary science) , surgery , chemotherapy , physics , astrobiology